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Abstract
Background: Diabetes is a prognostic factor for some malignancies, but its association with outcome in patients with
advanced or metastatic colorectal cancer (CRC) is less clear.
Methods: This cohort study was nested within a randomized trial of first-line chemotherapy and bevacizumab and/or cetuxi-
mab for advanced or metastatic CRC. Patients were enrolled at 508 community and academic centers throughout the
National Clinical Trials Network. The primary exposure was physician-documented diabetes at the time of enrollment. The
primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS) and adverse events.
Tests of statistical significance were two-sided.
Results: Among 2326 patients, 378 (16.3%) had diabetes. The median follow-up time was 6.0 years. We observed 1973 OS
events and 2173 PFS events. The median time to an OS event was 22.7 months among those with diabetes and 27.1 months
among those without diabetes (HR ¼ 1.27, 95% CI ¼ 1.13 to 1.44; P< .001). The median time to a PFS event was 9.7 months
among those with diabetes and 10.8 months among those without diabetes (HR ¼ 1.16, 95% CI ¼ 1.03 to 1.30; P¼ .02). Patients
with diabetes were more likely to experience no less than grade 3 hypertension (8.1% vs 4.4%; P¼ .054) but were not more
likely to experience other adverse events, including neuropathy.
Conclusions: Diabetes is associated with an increased risk of mortality and tumor progression in patients with advanced or
metastatic CRC. Patients with diabetes tolerate first-line treatment with chemotherapy and monoclonal antibodies similarly
to patients without diabetes.
Colorectal cancer (CRC) is the fourth most commonly diagnosed
cancer, and the second most common cause of cancer death in
the United States (1). Diabetes is also a leading cause of morbid-
ity and mortality in the United States (2). Diabetes is associated
with a 30% increased risk of developing CRC (3). At the time of
diagnosis of CRC, one in six patients will have preexisting diabe-
tes (4). Some studies, but not all, have demonstrated an associa-
tion between diabetes and higher risk of disease recurrence and
death in patients with localized or regional CRC (5–8). However,
the clinical implications of diabetes in patients with advanced
or metastatic CRC are less clear (9).
The biologic hallmark of type 2 diabetes is insulin resistance
and hyperglycemia (10). This metabolic status is relevant be-
cause CRC cells express insulin receptors, and exposure to insu-
lin and glucose promote cell proliferation, migration, and
invasion (11). A fluoropyrimidine with oxaliplatin (FOLFOX) or
Received: July 11, 2019; Revised: September 16, 2019; Accepted: September 20, 2019
© The Author(s) 2020. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
1 of 7
JNCI Cancer Spectrum (2020) 4(1): pkz078
doi: 10.1093/jncics/pkz078
First published online October 17, 2019
Article
irinotecan (FOLFIRI) are recommended as first-line chemother-
apy regimens for metastatic CRC (12). In vitro studies demon-
strate that hyperinsulinemia and hyperglycemia increase CRC
cell resistance to fluoropyrimidine, oxaliplatin, and irinotecan
therapies (13–15). Consequently, patients with metastatic CRC
and diabetes may be at an increased risk of tumor progression
and overall mortality compared with those patients with meta-
static CRC without diabetes.
Moreover, peripheral neuropathy is a common adverse
event of oxaliplatin (16). Patients with diabetes are susceptible
to the development or exacerbation of diabetic-related neuropa-
thy (17). Patients with diabetes develop neuropathy at lower cu-
mulative doses of oxaliplatin (18), demonstrating the increased
vulnerability of patients with diabetes to experience treatment-
related adverse events (19). However, evidence describing the
incidence of treatment-related adverse events in patients with
diabetes receiving therapy for advanced or metastatic CRC is
limited (20).
We prospectively examined the relationship between diabe-
tes with clinical outcome in a cohort of patients with advanced
or metastatic CRC who were enrolled in a National Cancer
Institute–sponsored randomized clinical trial of first-line che-
motherapy. In this trial, physicians selected FOLFOX or FOLFIRI
as the backbone chemotherapy regimen and then patients were
randomly assigned to targeted monoclonal antibody(s): cetuxi-
mab or bevacizumab or their combination (21). We hypothe-
sized that diabetes at trial enrollment would be associated with
lower physician selection of FOLFOX; shorter progression-free
survival; shorter overall survival; and higher incidence of
treatment-related adverse events, as compared with patients
without diabetes.
Methods
Study Design
Patients in this study participated in the National Cancer
Institute-sponsored Cancer and Leukemia Group B (CALGB; now
part of the Alliance for Clinical Trials in Oncology) 80405 trial of
chemotherapy plus biologic monoclonal antibodies for ad-
vanced or metastatic CRC. The initial clinical trial design com-
pared chemotherapy plus cetuximab; chemotherapy plus
bevacizumab; and chemotherapy plus cetuximab and bevacizu-
mab (ClinicalTrials.gov NCT00265850). After 3 years of enroll-
ment, the lack of efficacy for epidermal growth factor receptor
antibodies in KRAS-mutated tumors and the failure of dual-anti-
body combination treatments resulted in two consecutive
amendments that restricted eligibility to patients with KRAS
wild-type tumors (KRAS amendment) and closure of the dual-
antibody arm. The final clinical trial design compared chemo-
therapy plus cetuximab to chemotherapy plus bevacizumab
(21). However, this analysis included all patients, irrespective of
their KRAS status, who were randomly assigned to any of the
original three treatment arms.
Patient Eligibility
Eligibility for the treatment trial has been described (21). Briefly,
eligible patients had pathologically confirmed previously
untreated locally advanced or metastatic CRC. Patients were
aged 18 years and older, with an Eastern Cooperative Oncology
Group (ECOG) performance status of 01, and normal hepatic,
renal, and hematologic laboratory values. Patients had to be
candidates for either FOLFOX (fluorouracil, leucovorin, and oxa-
liplatin) or FOLFIRI (fluorouracil, leucovorin, and irinotecan)
chemotherapy regimens without known central nervous sys-
tem metastases or no less than grade 2 peripheral neuropathy
(neuropathy exclusion only applicable to patients whose physi-
cian chose FOLFOX). In addition, hypertension had to be well
controlled (blood pressure <160/90 mm Hg with treatment)
without concurrent congestive heart failure. Patients were
recruited from 508 study sites in the United States and Canada.
Institutional review board approval was required at all study
centers, and all patients provided written informed consent.
Diabetes Assessment
At the time of enrollment into the clinical trial, research staff
documented physician-diagnosed history of diabetes from the
medical record utilizing a standardized form. A subset of partic-
ipants also completed a self-reported questionnaire that
assessed a history of “physician-diagnosed diabetes or high
blood sugars” (see lifestyle substudy below for additional detail).
The primary analysis implemented a hierarchical approach that
used diabetes abstracted from the medical record and supple-
mented by the lifestyle substudy.
Study Endpoints
The primary endpoint of CALGB/SWOG 80405 (Alliance) and this
companion study was overall survival (OS). Secondary
endpoints were progression-free survival (PFS) and treatment-
related adverse events. OS was defined as the time from ran-
domization until death from any cause. Patients without
reported death were censored at their last known follow-up. PFS
was defined as the time from random assignment until first
documented evidence of tumor progression or death from any
cause. Patients were evaluated every 8 weeks for response with
radiologic imaging using the RECIST criteria [Version 1.0; (22)].
Tumor progression was determined by the treating physician.
Patients alive without documented tumor progression were
censored for progression at the most recent disease assess-
ment. Adverse events were assessed by the treating physician
or other qualified health-care provider every two weeks.
Adverse events were graded and attribution was assigned
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events [Version 3.0; (23)]. For
each patient, the maximum grade for each toxicity was
analyzed.
Covariates
Data for patient characteristics including age, sex, race, body
mass index, ECOG performance status, primary tumor
location, prior chemotherapy, prior radiotherapy, and primary
tumor resection status were obtained from a combination of
patient self-report, physician assessment, and the medical re-
cord. At the time of enrollment, patients could also optionally
participate in an observational lifestyle substudy (described
below).
Lifestyle Substudy
Patients who elected to enroll in the lifestyle substudy (1354 of
2334; 58%) were provided with a self-report questionnaire
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within the first month after random assignment that obtained
information regarding use of oral hypoglycemic medication
and/or insulin for “diabetes mellitus or high blood sugars” and
time since physician diagnosis of this condition. Patients who
enrolled in the lifestyle substudy also provided data that were
used as covariates in supplementary multivariable-adjusted
analyses.
Statistical Analysis
The primary statistical analysis compared clinical outcome by
diabetes status at the time of trial enrollment. The Wilcoxon
rank-sum test was used to compare the distribution of continu-
ous variables and v2 tests were used to compare the distribution
of categorical variables. Concordance between diabetes ab-
stracted from the medical record compared to self-reported dia-
betes in the lifestyle substudy was compared using kappa
coefficient (24). Cox proportional hazards regression models
were used to estimate the hazard ratio (HR) and 95% confidence
interval (CI) between diabetes status with OS or PFS (25). The
proportional hazards assumption was examined by including
time-dependent covariates in the regression models and visu-
ally inspecting log-log plots. Sensitivity analyses were con-
ducted using Fine-Gray competing risk regression models (26).
Subgroup effect modification was examined by testing the sta-
tistical interaction term between diabetes variable and sub-
group. Logistic regression models were used to estimate the
odds ratio (OR) and 95% confidence interval between diabetes
status and treatment-related adverse events. All analyses are
based on data freeze for long-term follow-up on January 8, 2018.
Data collection was conducted by the Alliance Statistics and
Data Center. A two-sided Pvalue less than .05 was considered
statistically significant.
Results
Patient Characteristics
This study was conducted between October 2005 and February
2012. Characteristics of the 2326 patients by diabetes status are
presented in Table 1. Of the patients, 378 had a medical record
of diabetes (16.3%). Patients with diabetes were older (63.0 vs
58.4 years; P< .001), had a higher body mass index (29.5 vs
26.7 kg/m2; P< .001), and poorer ECOG performance status
(46.8% vs 40.5% with ECOG PS 12; P¼ .02). Characteristics asso-
ciated with participation in the lifestyle substudy (Figure 1;
Supplementary Table 1, available online) and additional charac-
teristics associated with diabetes are presented as supplemen-
tary material (Supplementary Tables 2 and 3, available online).
Among participants who enrolled in the lifestyle substudy, the
agreement between medical record documentation of diabetes
and self-reported history of diabetes was high (Cohen j ¼ 0.83,
95% CI ¼ 0.79 to 0.87).
Associations Between Physician Selection of
Chemotherapy RegimenWith Diabetes
Patients with diabetes were less likely to receive FOLFOX (72.6
vs 78.1%; multivariable-adjusted P¼ .03) as the physician-
selected backbone chemotherapy regimen. This result was sim-
ilar when restricted to patients who had not received prior post-
operative chemotherapy (74.1% vs 82.9%; multivariable-
adjusted P< .001).
Associations Between Progression-Free and Overall
Survival With Diabetes
The median follow-up time from randomization was 6.0 years.
During follow-up, we observed 2173 PFS events and 1973 OS
events. The associations between diabetes with PFS and OS are
presented in Table 2. Patients with diabetes experienced shorter
OS than those without diabetes; the median OS was
22.7 months among those with diabetes and 27.1 months among
those without diabetes (multivariable-adjusted HR ¼ 1.27, 95%
CI ¼ 1.13 to 1.44; P< .001). Results were similar in competing-
risk regression models (Supplementary Table 4, available on-
line). Patients with diabetes experienced shorter PFS than those
without diabetes; the median PFS was 9.7 months among those
with diabetes and 10.8 months among those without diabetes
(multivariable-adjusted HR ¼ 1.16, 95% CI ¼ 1.03 to 1.30, P¼ .02).
In subgroup analyses, performance status modified the associa-
tion between diabetes and PFS (Pinteraction ¼ .02) but not OS
(P¼ .30; Figure 2). Patients with diabetes had a higher risk of PFS
with a poorer performance status (eg, ECOG 1). The above de-
scribed results were not substantively different when addition-
ally adjusted for covariates measured in the lifestyle substudy
that included physical activity, weight history, smoking history,
comorbid health conditions, and use of pharmacotherapy for
hyperlipidemia and hypertension (Supplementary Table 5,
available online).
Among those treated with FOLFOX, the proportion receiving
no less than 70% relative dose intensity of oxaliplatin did not
differ between patients with and without diabetes (65.5% vs
65.9%; multivariable-adjusted P¼ .92). Among those initially
treated with FOLFIRI, the proportion who received FOLFOX as a
second-line therapy was lower among patients with vs without
diabetes (48.9% vs 64.1%; multivariable-adjusted P< .001).
Associations Between Treatment-Related Adverse
Events With Diabetes
The associations between diabetes and adverse events are pre-
sented in Table 3. Patients with diabetes were more likely to ex-
perience no less than grade 3 hypertension at least possibly
related to treatment (8.1% vs 4.4%; multivariable-adjusted
P¼ .054). Patients with diabetes experienced similar rates of no
less than grade 2 neuropathy (36.6% vs 36.3%; multivariable-
adjusted P¼ .99). Results were similar in analyses that were
Figure 1. Consolidated Standards of Reporting Trials.
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additionally adjusted for covariates measured in the lifestyle
substudy (Supplementary Table 6 available online).
Associations Between Progression-Free and Overall
Survival With Diabetes, Stratified by Diabetes Therapy
and Duration of Diagnosis
The associations between diabetes with PFS and OS stratified by
patients who did and did not use insulin are presented in
Supplementary Table 7 (available online). The associations be-
tween duration of diabetes status with PFS and OS are pre-
sented in Supplementary Table 8 (available online).
Discussion
Physicians were more likely to select an irinotecan-containing
regimen (FOLFIRI) as a first-line chemotherapy backbone for
patients with diabetes when compared with patients without
diabetes; nevertheless, 72.6% of patients with diabetes were
treated with an oxaliplatin-containing regimen (FOLFOX).
Patients with advanced or metastatic CRC and diabetes experi-
enced a shorter time to tumor progression and overall mortality
when compared with patients without diabetes. These associa-
tions persisted after adjustment for established prognostic fac-
tors of tumor progression and survival. Except for hypertension,
patients with diabetes experienced a similar rate of treatment-
related adverse events compared with patients without
diabetes.
Diabetes is associated with the risk of developing and dying
from a variety of cancers, including CRC (27). In a systematic re-
view and meta-analysis of 26 studies of patients with CRC, dia-
betes was associated with a 17% increased risk of overall
mortality when compared with patients without diabetes (8).
However, studies conducted to date have often included smaller
sample sizes, with data obtained retrospectively from single in-
stitution hospital records or from registry and administrative
claims data. Moreover, studies often combine patients with
nonmetastatic and metastatic CRC, inconsistently measure out-
come events, and are limited in their ability to adjust for prog-
nostic or confounding variables, such as age, sex, performance
status, and body mass index (8,28).
Table 1. Baseline characteristics by diabetes status*
Characteristic No. (%) no diabetes (n¼ 1948; 83.7%) No. (%) diabetes (n¼378; 16.3%) P
Age, median (IQR), y 58.4 (50.2–66.8) 63.0 (55.2–70.6) <.001
Sex .37
Male 1127 (57.9) 228 (60.3)
Female 821 (42.1) 150 (39.7)
Race .30
White 1595 (81.9) 301 (79.6)
Black 224 (11.5) 54 (14.3)
Other/missing 129 (6.6) 23 (6.1)
Body mass index, median (IQR), kg/m2 26.7 (23.5–30.5) 29.5 (26.1–33.6) <.001
ECOG performance status .02
0 1160 (59.5) 201 (53.2)
1–2 788 (40.5) 177 (46.8)
Colorectal tumor location .12
Left 513 (26.3) 103 (27.2)
Transverse 136 (7.0) 33 (8.7)
Right 1136 (58.3) 200 (52.9)
Multiple or unknown 163 (8.4) 42 (11.1)
Protocol chemotherapy .001
FOLFIRI 420 (21.6) 110 (29.1)
mFOLFOX6 1528 (78.4) 268 (70.9)
Prior chemotherapy 277 (14.2) 57 (15.1) .66
Prior radiotherapy 165 (8.5) 40 (10.6) .19
Primary tumor unresected at study entry 450 (23.1) 81 (21.4) .48
KRAS amendment status .28
Pre-amendment 1197 (61.4) 221 (58.5)
Postamendment 751 (38.6) 157 (41.5)
Randomized treatment arm .60
Bevacizumab 743 (38.1) 154 (40.7)
Cetuximab 754 (38.7) 143 (37.8)
Bevacizumab þ Cetuximab 451 (23.2) 81 (21.4)
KRAS status .98
Wild-type 1088 (55.9) 211 (55.8)
Mutated 348 (17.9) 69 (18.3)
Unknown 512 (26.3) 98 (25.9)
Lifestyle substudy .21
Enrolled 1123 (57.6) 231 (61.1)
Declined 825 (42.4) 147 (38.9)
*ECOG ¼ Eastern Cooperative Oncology Group; FOLFIRI ¼ 5-fluorouracil, leucovorin, irinotecan; IQR ¼ interquartile range; mFOLFOX6 ¼ 5-fluorouracil, leucovorin,
oxaliplatin.
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Nesting a cohort study within a clinical trial to examine
the association of diabetes with clinical outcome offers sev-
eral advantages over the use of other data sources. First, our
prospective study included 2326 patients who were recruited
from 508 community and academic study sites throughout
the United States and Canada, which improves the represen-
tation of this trial population over prior studies. Second, be-
cause of uniform enrollment criteria, disease status of study
participants was well characterized, thereby reducing
unmeasured heterogeneity. Third, because this analysis was
conducted within the context of a therapeutic trial, treat-
ment, follow-up care, and endpoint ascertainment were con-
ducted according to a standardized protocol, and the date of
tumor progression was prospectively recorded, allowing for
consistent definition of PFS. Last, detailed information on
confounding variables such as age, sex, performance status,
and body mass index were collected from all participants.
Supplementary analyses of patients who enrolled in the life-
style substudy allowed for additional adjustment of potential
confounding variables such as physical activity, weight his-
tory, smoking history, comorbid health conditions, and select
medication use.
There are several important limitations of the current study.
Patients who enroll in a clinical trial may differ from the under-
lying population (29), thereby influencing the generalizability of
our findings. Patients with no less than preexisting grade 2 pe-
ripheral neuropathy at baseline were excluded from study en-
rollment if their physician desired to use FOLFOX, potentially
reducing the generalizability of our findings. However, because
our study population included patients recruited throughout
the United States and Canada in community and academic
sites, we believe that our findings may reflect the general popu-
lation of CRC patients who are appropriate candidates for sys-
temic therapy. Moreover, the 16.3% prevalence of diabetes at
enrollment is consistent with population-based estimates in
cancer patients (4). Diabetes status was obtained from the medi-
cal record at the time of trial enrollment. It is possible that there
is misclassification of diabetes as our exposure measure.
However, we would expect this misclassification to be nondif-
ferential with respect to clinical outcome and bias our effect
estimates toward the null. Because of the observational study
design, we cannot rule out the possibility of residual confound-
ing. However, the primary study endpoint, OS, was robust to ad-
justment for a variety of demographic-, clinical-, and
Figure 2. Subgroup analyses of progression-free survival and overall survival estimates by diabetes status. BMI, kg/m2. BMI ¼ body mass index; ECOG ¼ Eastern
Cooperative Oncology Group; FOLFIRI ¼ 5-fluorouracil, leucovorin, irinotecan; mFOLFOX6 ¼ 5-fluorouracil, leucovorin, oxaliplatin.
Table 2. Progression-free survival and overall survival estimates by diabetes status
Outcome and exposure
category
No. of
events
No. at
risk
Median time-to-event
(IQR) months
Unadjusted Multivariable adjusted*
HR (95% CI) P HR (95% CI) P
Progression-free survival
No diabetes 1816 1948 10.8 (10.4–11.1) 1.00 (Referent) — 1.00 (Referent) —
Diabetes 357 378 9.7 (9.2–10.5) 1.15 (1.02 to 1.29) .02 1.16 (1.03 to 1.30) .02
Overall survival
No diabetes 1638 1948 27.1 (25.9–28.5) 1.00 (Referent) — 1.00 (Referent) —
Diabetes 335 378 22.7 (20.0–24.6) 1.27 (1.13 to 1.43) <.001 1.27 (1.13 to 1.44) <.001
*The multivariable-adjusted regression model is adjusted for age, sex, race, body mass index, Eastern Cooperative Oncology Group performance status, colorectal tu-
mor location, protocol chemotherapy, prior chemotherapy, prior radiotherapy, intact primary tumor, randomized treatment arm, and KRAS status. CI ¼ confidence in-
terval; HR ¼ hazard ratio; IQR ¼ interquartile range.
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treatment-related covariates. In supplementary analyses, these
results persisted after multivariable adjustment for multiple be-
havioral and lifestyle factors. This study was designed prior to
seminal reports that described the antineoplastic properties of
metformin (30,31). Consequently, our questionnaire did not spe-
cifically inquire about the class of antidiabetic oral medication
precluding our ability to replicate this prior finding. Participants
who enrolled in the observational lifestyle substudy differed
from those who did not enroll on several demographic-, clini-
cal-, and treatment-related factors, which may limit generaliz-
ability of these; however, the prevalence of diabetes did not
differ (P¼ .21).
If the association between diabetes and clinical outcome is
causal, there are several plausible biologic pathways. The physio-
logic mechanisms that link diabetes with cancer outcomes may in-
clude hyperinsulinemia (including insulin-like growth factors and
their binding proteins), hyperglycemia, and inflammation (32).
Insulin resistance and resultant endogenous hyperinsulinemia
may promote gene transcription and cell growth and the inhibition
of apoptosis through activation of the PI3K-Akt-mTOR pathway
(32,33). Hyperglycemia may promote cell proliferation through the
generation of reactive oxygen species and subsequent activation of
the extracellular-signal-regulated kinases–mitogen-activated pro-
tein kinases pathway (32). Diabetes and body mass index were
marginally interactive with both PFS and OS. Among individuals
with diabetes, lower body mass index is associated with a higher
risk of cancer-specific and all-cause mortality (34). The biological
rationale proposed for this association is that diabetes in normal
weight has an increased genetic influence and more severe disease
(35,36). Further translational research is necessary to elucidate
these hypothesized physiologic mechanisms toward the goal of
identifying additional therapeutic targets.
If the association between diabetes and clinical outcome is
not causal, there are several plausible alternative explanations.
Patients with diabetes often have additional comorbid health
conditions, such as cardiovascular and pulmonary disease,
which are independently prognostic of clinical outcome.
However, in exploratory analyses, adjustment for these comor-
bid health conditions among patients who enrolled in the life-
style substudy modestly attenuated our effect estimates for OS.
We demonstrated that physicians less frequently use the
oxaliplatin-containing FOLFOX regimen in patients with diabe-
tes. Although the FOLFOX regimen and irinotecan-containing
FOLFIRI regimen have similar efficacy in the first-line setting for
advanced or metastatic CRC (12), patients with diabetes may
never receive treatment with oxaliplatin in later lines of ther-
apy. Our subgroup analyses did not identify an interaction effect
between diabetes and physician-selected chemotherapy
(P¼ .71) or randomized biologic therapy (P¼ .54). Further, there
was no effect modification by cytotoxic chemotherapy regimen
on outcomes; thus, patients who started on FOLFOX had similar
OS and PFS compared to those started on FOLFIRI. Last, it is pos-
sible that with the diagnosis of metastatic CRC, less attention is
devoted to glycemic management and control of other relevant
cardiovascular risk factors, which may increase overall morality
without directly influencing cancer growth or metastatic poten-
tial. However, we did observe a statistically significant effect of
diabetes on PFS, suggesting that diabetes may have a direct ef-
fect on tumor growth and progression.
In conclusion, our data support the hypothesis that diabetes is
associated with an increased risk of mortality and tumor progres-
sion in patients with metastatic CRC. These results underscore the
need for further research to understand the physiologic mecha-
nisms that underpin this relationship. Patients with diabetes toler-
ate first-line treatment with chemotherapy and monoclonal
antibodies similarly to patients without diabetes.
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